Long-acting injectable therapy offers an alternative to daily oral therapy, which can contribute to treatment fatigue, adherence challenges and emotional burden, according to Ricky Hsu, MD, national medical director at the AIDS Healthcare Foundation.
Among patients with HIV who were virologically suppressed and switched from oral therapy to long-acting injectable cabotegravir plus rilpivirine, 94% maintained a viral load below 50 copies per milliliter, researchers reported at IDWeek 2026. The finding was based on the last viral load measurement during patients’ first uninterrupted treatment course after completing treatment initiation.
Long-acting injectable therapy accounts for about 5% of all HIV prescriptions, Dr. Hsu said. Despite patient interest in the therapy, some physicians have questions about treatment persistence and effectiveness in routine care.
“Will they stick to the treatment? Will they continue to tolerate it and not stop the regimen because of injection site reactions? And will it be just as successful in the real world as the results that were seen in the randomized clinical trials?” he said.
The findings came from an abstract describing an observational analysis of the OPERA cohort. Researchers evaluated treatment persistence and virologic outcomes among adults who had previously received oral antiretroviral therapy and switched to injectable cabotegravir plus rilpivirine between Jan. 21, 2021, and Dec. 31, 2025, with follow-up through Feb. 28, 2026. Of 7,995 patients who switched, 6,955 (87%) had a viral load below 50 copies/mL at initiation.
Median age was 37 years; 23% of patients were 50 or older, 86% were male, 43% were Black and 32% were Hispanic. Most patients (78%) had a CD4 count of at least 500 cells/µL. Median time on their prior regimen was 21 months.
Among 6,362 of these patients who completed initiation — defined as receiving the first two injections no more than 67 days apart — 77% remained in care and on the injectable at study end, with or without treatment interruptions. Median treatment duration was 18 months. During their first uninterrupted treatment course, 94% had a viral load below 50 copies/mL at their last measurement, while 81% had viral loads below that threshold at every measurement.
Patients were also consistent with treatment, with 95% receiving their injections on time or having only one late injection within five days of the recommended window, according to Dr. Hsu. Confirmed virologic failure occurred in 1%, defined as two consecutive viral loads of at least 200 copies/mL or one viral load at that threshold followed by discontinuation.
Health care providers also completed electronic surveys about treatment discontinuation, defined as more than 127 days without an injection. Among 182 surveys of provider-confirmed discontinuations, representing 10% of discontinuations, the most common reported reasons were nonadherence to injection visits (29%), loss to care (23%) and a desire to switch to oral antiretroviral therapy (15%).
Dr. Hsu suggested that long-acting treatment may give patients “a sense of individual control and empowerment in their own health care.”
The abstract did not include financial disclosures or conflict-of-interest statements.